A detailed history of Eversept Partners, LP transactions in Vera Therapeutics, Inc. stock. As of the latest transaction made, Eversept Partners, LP holds 1,823,781 shares of VERA stock, worth $63.7 Million. This represents 5.9% of its overall portfolio holdings.

Number of Shares
1,823,781
Previous 1,914,830 4.75%
Holding current value
$63.7 Million
Previous $29.5 Million 167.03%
% of portfolio
5.9%
Previous 2.88%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$14.91 - $49.14 $1.36 Million - $4.47 Million
-91,049 Reduced 4.75%
1,823,781 $78.6 Million
Q4 2023

Feb 14, 2024

BUY
$9.29 - $16.0 $4.05 Million - $6.98 Million
436,341 Added 29.51%
1,914,830 $29.5 Million
Q3 2023

Nov 14, 2023

SELL
$13.71 - $19.64 $3.6 Million - $5.15 Million
-262,462 Reduced 15.08%
1,478,489 $20.3 Million
Q2 2023

Nov 08, 2023

SELL
$6.11 - $17.83 $290,701 - $848,315
-47,578 Reduced 2.66%
1,740,951 $27.9 Million
Q2 2023

Aug 14, 2023

SELL
$6.11 - $17.83 $290,701 - $848,315
-47,578 Reduced 2.66%
1,740,951 $27.9 Million
Q1 2023

Nov 08, 2023

BUY
$5.41 - $18.3 $7.45 Million - $25.2 Million
1,377,221 Added 334.84%
1,788,529 $13.9 Million
Q1 2023

May 15, 2023

BUY
$5.41 - $18.3 $7.45 Million - $25.2 Million
1,377,221 Added 334.84%
1,788,529 $13.9 Million
Q4 2022

Nov 08, 2023

BUY
$15.74 - $22.19 $4.02 Million - $5.66 Million
255,179 Added 163.44%
411,308 $7.96 Million
Q4 2022

Feb 14, 2023

BUY
$15.74 - $22.19 $4.02 Million - $5.66 Million
255,179 Added 163.44%
411,308 $7.96 Million
Q3 2022

Nov 08, 2023

SELL
$13.27 - $22.31 $21 Million - $35.4 Million
-1,584,822 Reduced 91.03%
156,129 $3.33 Million
Q3 2022

Nov 14, 2022

BUY
$13.27 - $22.31 $2.07 Million - $3.48 Million
156,129 New
156,129 $3.33 Million

Others Institutions Holding VERA

About Vera Therapeutics, Inc.


  • Ticker VERA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,042,300
  • Market Cap $945M
  • Description
  • Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...
More about VERA
Track This Portfolio

Track Eversept Partners, LP Portfolio

Follow Eversept Partners, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Eversept Partners, LP with notifications on news.